CGTN
23.3.2021 20:56:07 CET | Business Wire | Press release
As China's latest medium and long-term economic and social development plan was just approved at the country's top legislature, President Xi Jinping has left Beijing for his first inspection trip to east China's Fujian Province after the Two Sessions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323006017/en/
Xi's visits to an ecological tea garden and the Wuyishan National Park during the inspection show the importance he attaches to green, ecological development, which was also stressed in China's road map for development for the next five years and beyond.
Wuyi Mountain and ecological protection
Standing in the suburbs of Wuyishan City, Mount Wuyi entered UNESCO's list of World Heritage Sites in 1999. It covers an area of over 630 square kilometers and numerous types of tea are produced there.
Visiting mountains is usually arranged in Xi's inspection tours as construction of ecological civilization has always been stressed by the president.
In April 2020, Xi's first stop was also to visit the mountains. He went directly to the Qinling Mountains during his inspection in northwest China's Shaanxi Province to learn about ecological protection, urging officials to be guardians of ecological environment.
In August 2019, he went to northwest China's Gansu Province and visited the Qilian Mountains, underlining ecological protection as a national strategy.
On Monday, during his visit to the Wuyishan National Park, he encountered a group of tourists. "You can enjoy the mountain scenery in Wuyishan and enjoy the seascape in Xiamen City," he told the group.
Xi also visited the park's intelligent management center, where all the weather monitoring and services for biological resources within the park are conducted.
During the just-concluded Two Sessions, he said top-level design and comprehensive measures are needed to protect the ecosystems in mountains, rivers, forests, farmlands, lakes, grasslands and deserts.
Tea industry and rural vitalization
"In the past, the tea industry was a pillar in your fight against poverty, and it should become a pillar industry of rural vitalization in the future," Xi said on Monday at the tea garden.
He called for efforts to better cultivate a vibrant tea industry that takes advantage of Mount Wuyi's long history of tea culture, suitable climate, rich tea resources and the support of science and technology.
Shaking off poverty is not the finish line but the starting line of a new life and new endeavor, Xi said in February after announcing that China has secured a "complete victory" in its fight against poverty, urging efforts to effectively integrate the consolidation of poverty alleviation achievements and rural vitalization.
China detailed plans to fully promote the strategy of rural vitalization in the Chinese leadership's proposals for formulating the 14th Five-Year Plan (2021-2025) for National Economic and Social Development and the Long-Range Objectives Through the Year 2035.
Under this development blueprint, the country will push the development of industries with distinctive rural characteristics, cultivate new industries and modes of business, and encourage entrepreneurship and innovation in rural areas.
During his stop at the tea garden, Xi was pleased when hearing that the quality of tea was greatly improved through ecological planting in recent years, under the guidance of the team of technology commissioners.
Agricultural talents, also called "technological commissioners," was an idea introduced by Xi, the then governor to Fujian Province in a 2002 article, which called for bonding officials and farmers.
The president has stressed the role of science and technology in poverty alleviation and rural revitalization many times, calling for efforts to promote science and technological innovation in agriculture to support all-around rural revitalization.
During the inspection, Xi also visited a park dedicated to Zhu Xi, a renowned Chinese philosopher in the 12th century, in Nanping City on Monday afternoon, learning about local efforts to pass on traditional culture.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323006017/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
